Table of Contents:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. PARP Inhibitor Biomarkers Market: By Product Type Trends, Size, and Future Outlook
- By Product Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Product Type Definitions, Technology Landscape
- By Product Type Market Drivers
- Product Launches
- Technology Launches
- By Product Type Market Restraints
Chapter 4. PARP Inhibitor Biomarkers Market: By Cancer Type Trends, Size, and Future Outlook
- By Cancer Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Cancer Type Definitions, Technology Landscape
- By Cancer Type Market Drivers
- Product Launches
- Technology Launches
- By Cancer Type Market Restraints
Chapter 5. PARP Inhibitor Biomarkers Market: By Biomarker Type Trends, Size, and Future Outlook
- By Biomarker Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Biomarker Type Definitions, Technology Landscape
- By Biomarker Type Market Drivers
- Product Launches
- Technology Launches
- By Biomarker Type Market Restraints
Chapter 6. PARP Inhibitor Biomarkers Market: By Therapy Trends, Size, and Future Outlook
- By Therapy Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Therapy Definitions, Technology Landscape
- By Therapy Market Drivers
- Product Launches
- Technology Launches
- By Therapy Market Restraints
Chapter 7. PARP Inhibitor Biomarkers Market: By End User Trends, Size, and Future Outlook
- By End User Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By End User Definitions, Technology Landscape
- By End User Market Drivers
- Product Launches
- Technology Launches
- By End User Market Restraints
Chapter 8. PARP Inhibitor Biomarkers Market: By Distribution Channel Trends, Size, and Future Outlook
- By Distribution Channel Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Distribution Channel Definitions, Technology Landscape
- By Distribution Channel Market Drivers
- Product Launches
- Technology Launches
- By Distribution Channel Market Restraints
Chapter 9. PARP Inhibitor Biomarkers Market: Regional Market Trends, Size, and Future Outlook
- North America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Europe
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Asia Pacific
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Latin America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Middle East, and Africa
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
Chapter 10. PARP Inhibitor Biomarkers Market: Competitive Landscape
- AstraZeneca
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- GlaxoSmithKline
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Clovis Oncology
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Pfizer
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Merck & Co.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Abbvie
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Eisai Co.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Repare Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Artios Pharma
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Oncologie
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Ribon Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Arcus Biosciences
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Checkpoint Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Verastem Oncology
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Syros Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Sierra Oncology
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Tesaro
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Corcept Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Biomarin Pharmaceutical
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Aprea Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The current market size of the PARP Inhibitor Biomarkers industry is USD 2.8 billion in 2023.
Increasing cancer prevalence globally, rising adoption of biomarker testing, favorable reimbursement policies for treatment, and growing pipeline of PARP inhibitors.
High treatment costs of therapy, lack of awareness in underdeveloped regions, patent expiries of leading drugs, and drug resistance and side effects.
The leading component segment in the PARP Inhibitor Biomarkers Market is the olaparib segment, used for treating various cancers like ovarian, breast, and prostate.
AstraZeneca, GlaxoSmithKline, Clovis Oncology, Pfizer, Merck & Co., Abbvie, Eisai Co., Repare Therapeutics, Artios Pharma, and Oncologie.
The North America region is expected to lead the PARP Inhibitor Biomarkers Market, with a projected market size of USD 10.0 billion by 2031 and a CAGR of 17.2% during 2024-2031.
Increasing cancer prevalence, rising adoption of biomarker testing, favorable reimbursement policies, growing pipeline of PARP inhibitors, advancements in diagnostics, and emergence of novel drug delivery systems.